Arbutus Biopharma to Present at Jefferies London Healthcare Conference
Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on developing a cure for chronic hepatitis B virus (cHBV) infection, has announced its participation in the Jefferies London Healthcare Conference. The conference will feature a formal presentation by the Arbutus management team on Wednesday, November 15, 2023, at 11:30 am GMT / 6:30 am EDT.
Arbutus will not only present at the conference but will also host one-on-one meetings with investors. The event provides an opportunity for the company to showcase its progress and discuss its innovative approach to developing therapeutics for cHBV.
Accessing the Presentation
To access the live webcast of the presentation, interested individuals can visit the following link: [https://investor.arbutusbio.com/events-presentations](https://investor.arbutusbio.com/events-presentations). For those unable to attend the live event, an archived replay of the webcast will be available on the Arbutus website for a limited time.
About Arbutus Biopharma
Arbutus Biopharma Corporation is dedicated to leveraging its virology expertise to identify and develop novel therapeutics for patients with chronic hepatitis B virus. The company's pipeline includes promising compounds such as imdusiran (AB-729), an RNAi therapeutic, and AB-101, an oral PD-L1 inhibitor. These compounds have shown significant clinical data in reducing surface antigen and reawakening the HBV-specific immune response. Arbutus is committed to developing a functional cure for cHBV through a multi-faceted approach.
For more information about Arbutus Biopharma, please visit their website at [www.arbutusbio.com](www.arbutusbio.com).
For any inquiries from investors or the media, please contact Lisa M. Caperelli, Vice President of Investor Relations, at 215-206-1822 or firstname.lastname@example.org.
Arbutus Biopharma's Presentation at Jefferies London Healthcare Conference: Implications for New Businesses
Arbutus Biopharma's upcoming presentation at the Jefferies London Healthcare Conference could have significant implications for new businesses, particularly those in the biopharmaceutical sector. Arbutus, a clinical-stage biopharmaceutical company, is at the forefront of developing a cure for chronic hepatitis B virus (cHBV) infection. Their innovative approach and promising compounds, such as imdusiran (AB-729), an RNAi therapeutic, and AB-101, an oral PD-L1 inhibitor, are setting new standards in the industry.
New Business Opportunities
Arbutus's presentation and one-on-one meetings with investors at the conference could inspire new businesses to explore similar innovative approaches in their respective fields. The company's progress in developing therapeutics for cHBV could serve as a blueprint for startups seeking to make their mark in the biopharmaceutical sector.
Arbutus's proactive approach to investor relations, as evidenced by their one-on-one meetings at the conference, is a strategy that new businesses could learn from. Engaging with investors and keeping them informed about company progress can help secure crucial funding and support for a startup's growth and development.
In conclusion, Arbutus Biopharma's presentation at the Jefferies London Healthcare Conference is not just a significant event for the company, but also a potential source of inspiration and learning for new businesses.